Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated ...

Der er parkeringsplads lige bag biografen (Smedegades P-plads). Lørdag og søndag er der parkering uden tidsbegrænsning. Alle andre dage kan man holde der tre timer i tidsrummet 8-18. Kommer man efter ...

The global diabetes and obesity epidemic is driving another expansion of Novo Nordisk’s drug-manufacturing operations at its 264-acre campus in Clayton. The company will begin a $65 million expansion ...

Novo Nordisk Fonden tjener ikke kun milliarder på vægttabs- og diabetesmedicin ved at eje Novo Nordisk. Fonden ejer også en af verdens største leverandører af ingredienser til den globale ...

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...

This marks Novo Nordisk's second win this year in treating cardiovascular disease. The company develops a long line of blockbuster glucagon-like peptide-1 (GLP-1) agonists, including Ozempic ...

Danskere med type 2-diabetes eller svær overvægt vil fra næste uge få af et alternativ til de i forvejen kendte diabetes- og vægttabsmidler Ozempic og Wegovy fra danske Novo Nordisk. Det sker, når det ...

And Novo Nordisk is asking the U.S. Food and Drug Administration (FDA) to bar compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight ...

Shares in Novo Nordisk A/S (DK:NOVO.B) have lost a fifth of their market value since the end of June, the point at which the Danish pharma group revealed that it was committing around $4bn (£3.2bn) to ...